Back
How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion
Zofia Piotrowska, MD, MHS, and Lyudmila Bazhenova, MD, FASCO, discuss molecular testing, treatment sequencing, and adverse event monitoring in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, focusing on acquired MET-driven resistance after frontline osimertinib and EGFR exon 20 insertion disease that progresses after chemotherapy plus amivantamab.
How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion
Episodes
All
All
Please check back later for more content.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5
